Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer

Urology

Volumn 66, Issue 5, 2005, Pages 1024-1028

  Dvorak, Tomas ^b   Chen, Ming Hui ^b   Renshaw, Andrew A ^b   Loffredo, Marian ^b   Richie, Jerome P ^b   D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TUMOR VOLUME;

AGED; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE;

EID: 27744543928     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.05.037     Document Type: Article

References (30)

1. H.I. Scher, M. Mazumdar, W.K. Kelly Clinical trials in relapsed prostate cancer defining the target J Natl Cancer Inst 88 1996 1623 1634
2. B.D. Leibman, O. Dillioglugil, T.M. Wheeler Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level Cancer 76 1995 2530 2534
3. C.R. Pound, A.W. Partin, M.A. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
4. J.F. Ward, M.L. Blute, J. Slezak The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy J Urol 170 2003 1872 1876
5. T.A. Stamey, C.M. Yemoto, J.E. McNeal Prostate cancer is highly predictable a prognostic equation based on all morphological variables in radical prostatectomy specimens J Urol 163 2000 1155 1160
6. M. Noguchi, T.A. Stamey, J.E. McNeal Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens lack of significance of secondary cancers J Urol 170 2003 459 463
7. A.V. D'Amico, M.H. Chen, K.A. Roehl Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy N Engl J Med 351 2004 125 135
8. M.A. Khan, A.W. Partin, L.A. Mangold Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer Urology 62 2003 866 871
9. J.E. McNeal Cancer volume and site of origin of adenocarcinoma in the prostate relationship to local and distant spread Hum Pathol 23 1992 258 266
10. J.I. Epstein, M. Carmichael, A.W. Partin Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup J Urol 149 1993 1478 1481
11. E. Kikuchi, P.T. Scardino, T.M. Wheeler Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol 172 2004 508 511
12. M.L. Blute, E.J. Bergstralh, A. Iocca Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy J Urol 165 2001 119 125
13. T.A. Stamey, J.E. McNeal, C.M. Yemoto Biological determinants of cancer progression in men with prostate cancer JAMA 281 1999 1395 1400
14. P.A. Humphrey, R.T. Vollmer Intraglandular tumor extent and prognosis in prostatic carcinoma application of a grid method to prostatectomy specimens Hum Pathol 21 1990 799 804
15. A.A. Renshaw, H. Chang, A.V. D'Amico Estimation of tumor volume in radical prostatectomy specimens in routine clinical practice Am J Clin Pathol 107 1997 704 708
16. A.A. Renshaw, J.P. Richie, K.R. Loughlin Maximum diameter of prostatic carcinoma is a simple, inexpensive, and independent predictor of prostate-specific antigen failure in radical prostatectomy specimens validation in a cohort of 434 patients Am J Clin Pathol 111 1999 641 644
17. Group at VACUR D.F. Gleason Histologic grading and staging of prostatic carcinoma M. Tannenbaum Urologic Pathology. 1977 Lea & Febiger Philadelphia 171 187
18. American Joint Committee on Cancer and American Cancer Society F.L. Greene AJCC Cancer Staging Manual 2002 Springer New York 309 316
19. A.A. Renshaw An abbreviated protocol for processing radical prostatectomy specimens analysis of grade, stage, margin status, and volume J Urol Pathol 5 1996 183 192
20. D.R. Cox Regression models and life tables J R Stat Soc B 34 1972 187 199
21. D.G. Bostwick, S.D. Graham Jr, P. Napalkov Staging of early prostate cancer a proposed tumor volume-based prognostic index Urology 41 1993 403 411
22. M. Noguchi, T.A. Stamey, J.E. McNeal Assessment of morphometric measurements of prostate carcinoma volume Cancer 89 2000 1056 1064
23. M. Rashid, K.J. Wojno, R. Marcovich Maximum tumor dimension provides a clinically useful and independently significant measure for predicting PSA-free survival following radical prostatectomy J Urol 161 4S 1999 241
24. L.D. True Surgical pathology examination of the prostate gland practice survey by American Society of Clinical Pathologists Am J Clin Pathol 102 1994 572 579
25. G.S. Hall, C.E. Kramer, J.I. Epstein Evaluation of radical prostatectomy specimens a comparative analysis of sampling methods Am J Surg Pathol 16 1992 315 324
26. M. Haggman, M. Norberg, M. de la Torre Characterization of localized prostatic cancer distribution, grading and pT-staging in radical prostatectomy specimens Scand J Urol Nephrol 27 1993 7 13
27. A.E. Sehdev, C.C. Pan, J.I. Epstein Comparative analysis of sampling methods for grossing radical prostatectomy specimens performed for nonpalpable (stage T1c) prostatic adenocarcinoma Hum Pathol 32 2001 494 499
28. Z. Petrovich, G. Lieskovsky, B. Langholz Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate Int J Radiat Oncol Biol Phys 40 1998 139 147
29. A.V. D'Amico, A.A. Renshaw, K. Cote Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease J Clin Oncol 22 2004 3726 3732
30. A.V. D'Amico, J.W. Moul, P.R. Carroll Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 2003 1376 1383